[Cell adhesion molecules and pharmacologic applications. Round Table No 3 at Giens XIII].
This workshop intended to perform a "state-of-the art" of current research on adhesion molecules in various pathophysiologies, and to determine pharmacological targets. Indeed, recent important progress concerning the cellular and molecular physiology of adhesion molecules led to the development of various integrin antagonists in several domains, like cardiovascular disease, inflammation and cancer. Integrins play a major role in numerous process like embryonic development, tumor growth and metastasis, apoptosis, hemostasis, leucocyte recruitment and activation, and bone resorption. The development of integrin antagonists is well advanced in the cardiovascular domain, since the first marketed drug (abciximax, Reopro) is an antibody directed against the GPIIb/IIIa complex (integrin alpha IIb/beta 3) involved in the final pathway of platelet aggregation. Another active domain of research in pharmacology is 'cardioprotection', i.e. the prevention of cardiac damages induced by the reperfusion of the coronary bed after an ischemia secondary to thrombolysis, angioplasty, of coronary bypass. The pharmacological targets of these antagonists are integrins involved in various process like leucocyte and platelet adhesion and endothelial function. Other potential indications in the cardiovascular field are restenosis after angioplasty, and atherosclerosis.
McGregor
J
J
INSERM U 331, Lyon, France.
Berdeaux
A
A
Bonnet
J
J
Cambien
F
F
Fitzgerald
D
D
Lacolley
P
P
Lu
H
H
Le Saux Narjoz
A
A
Miossec
P
P
Netter
P
P
Poston
R
R
Laurent
S
S
D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000503:physiopathology; D015815:Cell Adhesion Molecules / Q000502:physiology*; D015195:Drug Design; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D016023:Integrins / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
D015815:Cell Adhesion Molecules; D016023:Integrins